Why age (and timing) really matters in developing drugs for neurodegenerative disease

ISSN： 1475-0708

Source： Therapy, Vol.8, Iss.5, 2011-09, pp. : 459-461

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drugs to Treat Age‐Related Neurodegenerative Problems The Final Frontier of Medical Science?

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 38, Iss. 6, 1990-06 ,pp. : 680-695

John Wiley & Sons Inc

Access to resources Recommend Favorite

Telling the truth: why disclosure matters in chronic kidney disease

By Gelipter David

British Journal of General Practice, Vol. 62, Iss. 601, 2012-08 ,pp. : 408-408

Royal College of General Practitioners

Access to resources Recommend Favorite

Telling the truth: why disclosure matters in chronic kidney disease

By Abdi Zeinab Gallagher Hugh O'Donoghue Donal

British Journal of General Practice, Vol. 62, Iss. 597, 2012-04 ,pp. : 172-173

Royal College of General Practitioners

Access to resources Recommend Favorite

Telling the truth: why disclosure matters in chronic kidney disease

By Cave James

British Journal of General Practice, Vol. 62, Iss. 600, 2012-07 ,pp. : 348-349

Royal College of General Practitioners

Access to resources Recommend Favorite

Dopamine and Serotonin Systems in Human and Rodent Brain: Effects of Age and Neurodegenerative Disease

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 35, Iss. 4, 1987-04 ,pp. : 334-345

John Wiley & Sons Inc

Access to resources Recommend Favorite